Clinical trials: Nontuberculous Mycobacterial Infection
Pain, Neuropathic, Leprosy
Treatment of Neuropathic Pain in Leprosy
Despite large efforts to eradicate leprosy, this curable mycobacterial infection still affects 250,000 new individuals annually. Half of the globe's leprosy patients live in Brazil and India.
- Conditions
- Pain, Neuropathic, Leprosy, Leprosy Neuropathy, Amitriptyline
- Trial name
- AmyNeLe (NCT03324035)
- Testing
- Amitriptyline, Tramadol
- Where
- Brazil
- Volunteers
- 102 people
- Sponsor
- University of Sao Paulo
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
To compare the efficacy and safety of clarithromycin combined with rifabutin, ethambutol, or both in the treatment of disseminated Mycobacterium avium Complex (MAC) disease in persons with AIDS, including individuals who have or…
- Trial name
- NCT00001058
- Testing
- Indinavir sulfate, Ritonavir, Ethambutol hydrochloride
- Where
- 34 sites in United States, Tanzania
- Volunteers
- 246 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
GATA2 Deficiency
Natural History Study of GATA2 Deficiency and Related Disorders
Background: GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it.
- Trial name
- NCT01905826
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nontuberculous Mycobacterial Infections
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
- Trial name
- NCT03164291
- Testing
- Rifabutin
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- The University of Texas Health Science Center at Tyler
Nontuberculous Mycobacterial Disease, Atypical Mycobacterium Infections
Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease
Little is known about the disease caused by the nontuberculous or environmental mycobacteria (NTM) and only limited data are available showing treatment outcome.
- Trial name
- NCT01680822
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Illinois Chicago
Mycobacterium Infections, Nontuberculous
A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections
The study aims to address the following aims 1. To provide an overview of the epidemiology of the patients who are managed in the Singapore General Hospital for NTM infections. 2.
- Trial name
- NCT02355015
- Where
- Singapore
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Nontuberculous Mycobacterial Diseases
Pharmacokinetic Study With a Loading Dose of Clofazimine in Adult Patients With Nontuberculous Mycobacterial Disease
Clofazimine (CFZ) is a promising drug for the treatment of NTM diseases. CFZ is highly active in vitro against M. abscessus and M. avium, the most common NTM pathogens, and shows synergy with macrolides and amikacin.
- Trial name
- C-LOAD (NCT05294146)
- Testing
- Clofazimine
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Radboud University Medical Center
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
The purpose of this study is to evaluate the safety of progressively substituting day +3 and +4 post-transplant cyclophosphamide (PT-CY) with post-transplant bendamustine (PT-BEN) in myeloablative (MAC) haploidentical…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT02996773
- Testing
- Bendamustine, Cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arizona
Obesity, Leprosy
Effect of Weight and/or Obesity on Dapsone Drug Concentrations
This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.
- Conditions
- Obesity, Leprosy, Tuberculosis
- Trial name
- NCT01165840
- Testing
- Dapsone
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Lepromatous Leprosy
Microcirculatory Impairment in Patients With Leprosy
In this study the investigators have aimed to evaluate morphology and reactivity of cutaneous microcirculation in patients with lepromatous leprosy.
- Trial name
- NCT02085317
- Testing
- acetylcholine Iontophoresis, sodium nitroprusside Iontophoresis
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Curt Treu
Leprosy
Uniform Multidrug Therapy Regimen for Leprosy Patients
The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment.
- Trial name
- U-MDT (NCT00669643)
- Testing
- PB 6 doses - Rifampicin and Dapsone, PB 6 doses - Rifampicin, Clofazimine and Dapsone, MB 12 doses - Rifampicin, Clofazimine and Dapsone
- Where
- 2 sites in Brazil
- Volunteers
- 859 people
- Sponsor
- University of Brasilia
Nontuberculous Mycobacterium Infection
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
The purpose of this study is to evaluate the efficacy and safety of open-label exposure of gNO in patients with NTM lung disease. Subjects will receive the study drug by inhaling through a nasal mask.
- Trial name
- NCT03748992
- Testing
- gNO
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Mycobacterium Avium-Intracellulare Infection
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
This study will test the safety and effectiveness of inhaled interferon gamma-1b and oral antibiotics for treating mycobacterium avium complex (MAC) infection of the lungs.
- Trial name
- NCT00021567
- Testing
- Interferon Gamma for Aerosol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Abscessus Infection, Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies
Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome
The treatment outcome of Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has not been well studied.
- Conditions
- Mycobacterium Abscessus Infection, Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies, Nontuberculous Mycobacterial Pulmonary Infection
- Trial name
- NCT05354583
- Testing
- Appropriate treatment
- Where
- Thailand
- Volunteers
- 36 people
- Sponsor
- King Chulalongkorn Memorial Hospital
Leprosy
Leprosy Skin Test Antigens Phase 1
This is a small Phase I trial to evaluate the safety of the use as skin test antigens of the immunologically active proteins from the soluble/cytosol and insoluble cell wall of Mycobacterium leprae.
- Trial name
- NCT01920750
- Testing
- MLCwA, MLSA-LAM, Mock Antigen
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Leprosy, Disability Evaluation
Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients
Leprosy is an infectious disease of slow evolution, manifested primarily by signs and symptoms dermatoneurological with skin lesions and peripheral nerve, especially in the eyes, hands and feet.
- Conditions
- Leprosy, Disability Evaluation, Quality of Life
- Trial name
- NCT01006759
- Testing
- exercise and orientation
- Where
- Brazil
- Volunteers
- 55 people
- Sponsor
- University of Sao Paulo
Mycobacterium Avium-Intracellulare Infection, HIV Infections
The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients
To determine if treatment of MAC infection in HIV-1 infected persons is associated with the decreases in plasma levels of TNF-alpha. Infection with MAC is a poor prognostic indicator in persons with AIDS.
- Trial name
- NCT00000860
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Modulation, Tuberculosis
CD8 Reactivity to Microorganisms in Blood and Breast Milk
Background: When a person is exposed to something that causes an infection, the body sends a type of cell called CD8 T cells to attack it. Those cells are also found in breast milk.
- Conditions
- Immune Modulation, Tuberculosis, Leprosy, Pertussis
- Trial name
- NCT03084614
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous
Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)
The purpose of this study is to find out if the Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine can be used safely to treat Mycobacterium avium complex (MAC) lung disease.
- Trial name
- BOOST (NCT07094711)
- Testing
- Mycobacterium bovis Bacillus Calmette Guerin (BCG) vaccine, preservative-free saline
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Virginia